Lidds AB

Lidds AB is an innovative pharmaceutical company focused on enhancing drug delivery technologies. Utilizing its proprietary NanoZolid® technology, Lidds AB develops injectable drug delivery systems that target specific areas within the body for precise treatment. This advanced approach allows for slower, controlled release of drugs, minimizing systemic exposure and potentially reducing side effects, making it particularly impactful in the oncology sector. Lidds AB strives to improve patient outcomes in therapeutic areas such as prostate cancer and other solid tumors. Headquartered in Uppsala, Sweden, the company collaborates with major pharmaceutical firms to extend its reach. The significance of Lidds AB in the financial market is tied to its potential for innovation in drug delivery systems, offering partnerships and licensing deals with larger pharmaceutical players, and addressing a substantial unmet medical need. Its technology is a testament to the growing importance of precision medicine, reflecting a trend toward more localized and efficient healthcare solutions globally.